4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California. Show more

Location: 5858 Horton Street, Emeryville, CA, 94608, United States | Website: https://www.4dmoleculartherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

177.9M

52 Wk Range

$2.23 - $28.93

Previous Close

$3.84

Open

$3.86

Volume

235,648

Day Range

$3.71 - $3.89

Enterprise Value

-119.7M

Cash

321.4M

Avg Qtr Burn

-38.31M

Insider Ownership

3.88%

Institutional Own.

95.91%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
4D-150 Details
Wet age-related macular degeneration

Phase 2b

Data readout

4D-150 Details
Diabetic macular edema

Susp. Mover™

Phase 2

Data readout

4D-310 Details
Fabry disease

Phase 1/2

Data readout

4D-710 Details
Cystic fibrosis

Phase 1/2

Data readout

4D-175 Details
Geographic atrophy

Phase 1

Update

4D-125 Details
X-linked retinitis pigmentosa

Failed

Discontinued

4D-110 Details
Choroideremia

Failed

Discontinued